Another study found that bromodomain and extra-terminal domain inhibitors could be used to reduce the levels of B7-H3 protein and mRNA in pancreatic cancer cells, providing a new therapeutic strategy to overcome immune and chemotherapy resistance in pancreatic cancer (21). This evidence concerns the gene CD276 and pancreatic neoplasm.